Obesity Trials Widen Net Loss: Massive Cash Reserves Secure Runway (VKTX Q4 2025 Earnings Call)

By Dr. Graph | Updated on May 31, 2026 | earnings

Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.

Viking Therapeutics reported widening net losses for both the fourth quarter and the full year as the company accelerated its obesity pipeline into late-stage clinical trials. This operational expansion represents a crucial turning point, positioning the biotechnology firm to potentially deliver the industry's first oral and subcutaneous dual-agonist weight loss platform.

Clinical Development Surge Drives Quarterly Loss Expansion

Gregory Zante, Viking Therapeutics Chief Financial Officer, reported research and development expenses of $153.5 million for the fourth quarter. This represents a significant increase in development costs compared to the prior year. The surge was primarily driven by expenses associated with running the late-stage trials. Meanwhile, general and administrative expenses fell due to lower legal costs. These dynamics resulted in a quarterly net loss of $157.7 million, which translates to $1.38 per share.

Full Year Spending Accelerates in Obesity Pipeline Push

For the full year, research and development expenses reached $345 million as clinical studies expanded. This substantial investment reflects the company's commitment to advancing its obesity pipeline. The increased R&D spend was the primary driver of the widened full-year net loss of $358.5 million. On a per-share basis, the net loss climbed to $3.19. Despite the growing expenses, G&A costs decreased slightly due to legal savings.

Massive Capital Runway Secures Upcoming Clinical Catalysts

To fund these extensive trials, the company is leveraging its solid capital reserves. Chief Financial Officer Gregory Zante stated that the firm "held cash, cash equivalents and short-term investments of $706 million" to close out the year. Management confirmed that this balance is sufficient to fund three upcoming clinical catalysts. This runway will take the subcutaneous and oral studies through their next major readouts.

Subcutaneous Program Reaches Pivotal Registration Milestones

The company's subcutaneous formulation, VK2735, is advancing rapidly in Phase III trials. The VANQUISH-1 study, which targeted approximately 4,500 patients, completed enrollment ahead of schedule. Meanwhile, enrollment is nearing completion for the VANQUISH-2 study, which is targeting approximately 1,100 patients. Prior Phase II trials of the injectable dual-agonist demonstrated encouraging results, achieving up to 14.7% weight loss. Additionally, a completed bioequivalent study enables a transition to an auto-injector device.

Oral Formulation Efficacy Supports Novel Maintenance Strategies

Viking's oral tablet also demonstrated strong performance, achieving up to 12.2% weight loss in Phase II. To assess maintenance, researchers transitioned participants to a lower 30-milligram daily dose. The down-titration study showed progressive weight reduction, with patients reaching 9.2% weight loss. To prepare for eventual commercialization, the company secured a broad manufacturing agreement with CordenPharma. CEO Brian Lian stated that this agreement supports a multibillion-dollar opportunity.

Strategic Hires and Pipeline Breadth Drive Future Success

Viking is actively building its commercial infrastructure as the pipeline matures. The firm appointed Neil Aubuchon as Chief Commercial Officer to lead the launch strategy. Aubuchon brings deep expertise to the role, including nearly 17 years at Eli Lilly. To further test dosing flexibility, the company's maintenance study administers weekly doses for 19 weeks. Results are expected soon, alongside the IND filing for the novel amylin program.

Frequently Asked Questions

What clinical milestones did Viking Therapeutics achieve with its subcutaneous obesity program?

Viking initiated its Phase III VANQUISH program, completing enrollment for the VANQUISH-1 trial ahead of schedule. The company also completed a bioequivalent study enabling the transition of participants to an auto-injector device.

What were the weight loss results for the oral formulation of VK2735 in early trials?

In the Phase I study, daily oral doses of VK2735 demonstrated weight reductions of up to 8.2% after 28 days of daily administration.

What proportion of patients achieved significant weight loss in the oral Phase II study?

In the VENTURE-Oral trial, up to 80% of participants in the treatment groups achieved at least 10% weight loss after once-daily dosing. In comparison, only 5% of the patients who received the placebo achieved this result.

How much cash did Viking Therapeutics hold at the end of the prior fiscal year?

Viking held $903 million in cash, cash equivalents, and short-term investments at the end of the prior year, before accelerating its clinical programs.

When does Viking Therapeutics expect to release results for the Phase I maintenance study?

The company completed enrollment in the maintenance dosing trial and plans to release the top-line results later this year.